ES8507128A1 - Piperidine derivatives. - Google Patents

Piperidine derivatives.

Info

Publication number
ES8507128A1
ES8507128A1 ES534439A ES534439A ES8507128A1 ES 8507128 A1 ES8507128 A1 ES 8507128A1 ES 534439 A ES534439 A ES 534439A ES 534439 A ES534439 A ES 534439A ES 8507128 A1 ES8507128 A1 ES 8507128A1
Authority
ES
Spain
Prior art keywords
group
atom
alkyl group
lower alkyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES534439A
Other languages
Spanish (es)
Other versions
ES534439A0 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fordonal SA
Original Assignee
Fordonal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10546879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8507128(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fordonal SA filed Critical Fordonal SA
Publication of ES534439A0 publication Critical patent/ES534439A0/en
Publication of ES8507128A1 publication Critical patent/ES8507128A1/en
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compounds of the general formula I: < IMAGE > I wherein R1 represents a thienyl group, or a phenyl group optionally substituted by a halogen (preferably fluorine or chlorine) atom, a lower alkoxy or lower alkyl group, R2 represents a hydrogen or halogen (preferably fluorine) atom, a lower alkoxy or lower alkyl group, R3 represents a hydrogen or halogen (preferably fluorine) atom, a lower alkylthio, lower alkoxy or lower alkyl group, or a cycloalkyl group containing 5 or 6 carbon atoms, or a group of the general formula: < IMAGE > II wherein R4 and R5 singly each represents a hydrogen atom or lower alkyl group, R6 represents a cycloalkyl, hydroxymethyl, carboxy or lower alkoxycarbonyl group, and W represents a carbonyl < IMAGE > or a hydroxymethylene [viz. -CH(OH)-] group, and pharmacologically acceptable salts thereof possess potent selective Histamine H1-receptor blocking and calcium antagonist properties and are of interest in the treatment of a variety of respiratory, allergenic and cardiovascular disease states. The new compounds can be prepared by various methods based on the condensation of alpha -substituted benzyl halides with N-(benzoylpropyl or phenyl-hydroxypropyl)-4-hydroxy piperidines or condensation of di-substituted-methoxy-piperidines with a benzoylpropyl halide or a phenyl-hydroxypropyl-halide followed, where necessary, by removal of protecting groups.
ES534439A 1983-08-05 1984-07-19 Piperidine derivatives. Expired ES8507128A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB838321157A GB8321157D0 (en) 1983-08-05 1983-08-05 Piperidine derivatives

Publications (2)

Publication Number Publication Date
ES534439A0 ES534439A0 (en) 1985-09-01
ES8507128A1 true ES8507128A1 (en) 1985-09-01

Family

ID=10546879

Family Applications (5)

Application Number Title Priority Date Filing Date
ES534435A Expired ES8505979A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.
ES534438A Expired ES8505980A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.
ES534436A Expired ES8507127A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.
ES534437A Expired ES8506298A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.
ES534439A Expired ES8507128A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.

Family Applications Before (4)

Application Number Title Priority Date Filing Date
ES534435A Expired ES8505979A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.
ES534438A Expired ES8505980A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.
ES534436A Expired ES8507127A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.
ES534437A Expired ES8506298A1 (en) 1983-08-05 1984-07-19 Piperidine derivatives.

Country Status (22)

Country Link
US (1) US4550116A (en)
EP (1) EP0134124B1 (en)
JP (1) JPS6094962A (en)
KR (1) KR910009937B1 (en)
AT (1) ATE30418T1 (en)
AU (1) AU565293B2 (en)
CA (1) CA1264324A (en)
DE (2) DE3466982D1 (en)
DK (1) DK158348C (en)
EG (1) EG16936A (en)
ES (5) ES8505979A1 (en)
FI (1) FI81567C (en)
GB (1) GB8321157D0 (en)
GR (1) GR80031B (en)
HU (1) HU196370B (en)
IL (1) IL72465A (en)
MX (2) MX156547A (en)
MY (1) MY101017A (en)
NZ (1) NZ209023A (en)
PH (1) PH19880A (en)
PT (1) PT79028B (en)
ZA (1) ZA845968B (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673684A (en) * 1984-04-04 1987-06-16 Terumo Corporation Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient
JPS625956A (en) * 1985-07-02 1987-01-12 Terumo Corp Vinyl derivative and 5-lipoxygenase action inhibitor containing same
US4766215A (en) * 1987-02-27 1988-08-23 American Home Products Corporation Histamine H1 -receptor antagonists
US4929618A (en) * 1988-03-25 1990-05-29 Ube Industries, Ltd. Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same
US5231104A (en) * 1988-07-08 1993-07-27 Pfizer Inc. 1-arylethyl-3-substituted piperidines
CA2015949A1 (en) * 1989-05-22 1990-11-22 Yasuo Ito Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
FR2655649B1 (en) * 1989-12-12 1994-07-08 Adir NOVEL PIPERIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
DE4034218A1 (en) * 1990-10-27 1992-04-30 Merck Patent Gmbh METHOD FOR PRODUCING CAREBASTIN
JP2624372B2 (en) * 1990-11-15 1997-06-25 宇部興産株式会社 Diarylmethoxypiperidine derivative
FR2673842B1 (en) * 1991-03-13 1993-12-24 Rhone Poulenc Rorer Sa NOVEL LIQUID COMPOSITIONS BASED ON 1,4-SUBSTITUTED PIPERIDINE DERIVATIVES.
US5190959A (en) * 1991-08-08 1993-03-02 Kaken Pharmaceutical Co. Ltd. Piperidine compounds which have useful pharmaceutical activity
FR2684298B1 (en) * 1991-12-03 1994-03-11 Rhone Poulenc Rorer Sa NOVEL SOLID PHARMACEUTICAL COMPOSITIONS BASED ON 1,4-SUBSTITUTED LAPIPERIDINE DERIVATIVES.
PT1026147E (en) * 1993-06-24 2004-04-30 Albany Molecular Res Inc UTERIC COMPOUNDS AS INTERMEDIARIES IN THE PRODUCTION OF PIPERIDINE DERIVATIVES
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
CN1275916C (en) 1993-06-25 2006-09-20 阿温蒂斯公司 Novel intermediates useful for the preparation of antihistaminic piperidine derivatives
US6147216A (en) * 1993-06-25 2000-11-14 Merrell Pharmaceuticals Inc. Intermediates useful for the preparation of antihistaminic piperidine derivatives
KR100362620B1 (en) 1994-08-25 2003-02-14 메렐 파마슈티칼스 인크. Substituted piperidines useful for the treatment of allergic diseases, pharmaceutical compositions comprising them and methods for their preparation
AU705427B2 (en) * 1995-05-08 1999-05-20 Aventisub Ii Inc. Alpha-(substituted alkylphenyl) -4-(hydroxydiphenylmethyl)-1-piperidine butanol derivatives, their preparation and their use as anti-histamines, anti-allergy agents and bronchodilators
US6211199B1 (en) 1995-11-17 2001-04-03 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
US6194406B1 (en) 1995-12-20 2001-02-27 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
US6423704B2 (en) 1995-12-20 2002-07-23 Aventis Pharmaceuticals Inc. Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6201124B1 (en) * 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US5998439A (en) 1996-02-21 1999-12-07 Hoescht Marion Roussel, Inc. Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5932571A (en) * 1996-02-21 1999-08-03 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US6541479B1 (en) * 1997-12-02 2003-04-01 Massachusetts College Of Pharmacy Calcium channel blockers
US6673933B2 (en) 1998-07-02 2004-01-06 Aventis Pharmaceutical Inc. Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6683094B2 (en) 1998-07-02 2004-01-27 Aventis Pharmaceuticals Inc. Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7498443B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) * 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2231043B2 (en) * 2004-10-29 2005-10-01 Laboratorios Cinfa, S.A. PHARMACEUTICAL COMPOSITION OF EBASTINE FOR IMMEDIATE RELEASE AND ITS MANUFACTURING PROCESS.
WO2006080415A1 (en) * 2005-01-31 2006-08-03 Y's Therapeutics Co., Limited Composition and method for treating or preventing bladder disorder
EP1898882B1 (en) * 2005-06-09 2009-10-28 Elan Pharma International Limited Nanoparticulate ebastine formulations
KR20080065704A (en) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 Methods, compositions, and kits for the treatment of medical conditions
CN100443470C (en) * 2006-07-21 2008-12-17 杭州保灵有限公司 Prepn of ebastine
DE102008000351B4 (en) 2008-02-20 2017-08-10 Aristo Pharma Gmbh Process for the preparation of an ebastine-containing granule and a solid pharmaceutical composition, ebastine-containing granules and its use
PT2009157006W (en) 2008-06-26 2012-10-17 Micro Labs Ltd Processo of preparing ebastine
WO2010021681A2 (en) * 2008-08-18 2010-02-25 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
US20110130711A1 (en) * 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
EP2371817A1 (en) 2010-04-01 2011-10-05 Arevipharma GmbH Process for the preparation of 1-[4-(1,1-dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone and acid addition salts thereof
DE202011000756U1 (en) 2011-03-31 2011-10-12 Micro Labs Limited Ebastins, non-micronised ebastine particles and pharmaceutical compositions comprising ebastines
WO2013081562A1 (en) 2011-10-13 2013-06-06 Mahmut Bilgic Oral formulations comprising ebastine
WO2013062498A1 (en) * 2011-10-13 2013-05-02 Mahmut Bilgic Solid oral formulations comprising ebastine
EP2589376B1 (en) 2011-11-01 2016-09-21 Inopharm Limited Oral disintegrating composition of anti-histamine agents
CN109593058B (en) * 2019-01-23 2021-09-24 江苏联环药业股份有限公司 Preparation method of ebastine
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022106923A1 (en) 2020-11-18 2022-05-27 BioPharma Synergies, S. L. Orodispersible powder composition comprising an antihistamine compound
CN112574097B (en) * 2020-12-21 2023-01-03 杭州仟源保灵药业有限公司 Preparation method of Ebastine and fumarate thereof
CN114014796A (en) * 2021-11-16 2022-02-08 江苏联环药业股份有限公司 Epstein salt and preparation method and application thereof
CN116496205A (en) * 2022-05-06 2023-07-28 成都施贝康生物医药科技有限公司 Cardustatin salt and application thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB688354A (en) * 1950-04-07 1953-03-04 Nopco Chem Co Improvements relating to compounds of the benzhydryl ether type
US2716122A (en) * 1953-10-19 1955-08-23 Nopco Chem Co N-substituted-4-benzhydryl ether-piperidines
GB895309A (en) * 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3080372A (en) * 1960-03-25 1963-03-05 Res Lab Dr C Janssen 1-aroylalkyl-4-arylpiperidine derivatives
GB963639A (en) * 1960-10-20 1964-07-15 Arnold Heyworth Beckett New piperidine derivatives and processes for preparing the same
BE615410A (en) * 1961-03-22
DE1645968A1 (en) * 1966-05-09 1972-04-06 Aldrich Chem Co Inc Piperidine derivatives and processes for their preparation
US3446014A (en) * 1968-01-17 1969-05-27 Struthers Energy Systems Inc Pulverizer
US3679666A (en) * 1969-04-03 1972-07-25 Hoffmann La Roche 4-(4-hydroxypiperidino)-4'-fluorobutyrophenones
US3799932A (en) * 1970-03-20 1974-03-26 Sumitomo Chemical Co Gamma-piperidinobutyrophenones
US3743645A (en) * 1970-10-19 1973-07-03 Robins Co Inc A H 1-substituted-4-phenoxypiperidines
US4070473A (en) * 1973-01-26 1978-01-24 Ab Ferrosan Piperidino-butyrophenones
FI60559C (en) * 1975-07-17 1982-02-10 Sumitomo Chemical Co FOERFARANDE FOER FRAMSTAELLNING AV NY- (TERTIAER AMINO) -ORTO-AMINOBUTYROFENONFOERENINGAR
US4424357A (en) * 1979-02-23 1984-01-03 Hoechst-Roussel Pharmaceuticals, Inc. Process for preparing 4-aryloxy-3-phenylpiperidines
US4216218A (en) * 1979-02-23 1980-08-05 American Hoechst Corporation Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
US4312876A (en) * 1979-02-23 1982-01-26 Hoechst-Roussel Pharmaceuticals Incorporated Antidepressive and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines
FR2450816A1 (en) * 1979-03-09 1980-10-03 Metabio Joullie Sa NOVEL PIPERIDINE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
IE49998B1 (en) * 1979-08-06 1986-01-22 Merrell Dow Pharma 4-(naphthalenyloxy)piperidine derivatives
ATE13425T1 (en) * 1981-10-15 1985-06-15 Synthelabo PIPERIDINE DERIVATIVES, PROCESSES FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS.

Also Published As

Publication number Publication date
DK378784D0 (en) 1984-08-03
IL72465A (en) 1988-08-31
ES534437A0 (en) 1985-07-16
ES534439A0 (en) 1985-09-01
EG16936A (en) 1994-02-28
DE19875026I2 (en) 2002-01-31
CA1264324A (en) 1990-01-09
ES8506298A1 (en) 1985-07-16
MY101017A (en) 1991-06-29
ES534438A0 (en) 1985-07-01
AU565293B2 (en) 1987-09-10
HU196370B (en) 1988-11-28
NZ209023A (en) 1988-02-29
FI843053A0 (en) 1984-08-02
ES534436A0 (en) 1985-09-01
FI81567C (en) 1990-11-12
ES8507127A1 (en) 1985-09-01
FI81567B (en) 1990-07-31
ATE30418T1 (en) 1987-11-15
JPS6094962A (en) 1985-05-28
DK158348B (en) 1990-05-07
AU3146584A (en) 1985-02-14
PT79028B (en) 1986-08-22
DK378784A (en) 1985-02-06
EP0134124A1 (en) 1985-03-13
MX156547A (en) 1988-09-06
JPH0432821B2 (en) 1992-06-01
ZA845968B (en) 1985-03-27
DE3466982D1 (en) 1987-12-03
EP0134124B1 (en) 1987-10-28
US4550116A (en) 1985-10-29
MX9203149A (en) 1992-07-01
GB8321157D0 (en) 1983-09-07
PH19880A (en) 1986-08-13
DK158348C (en) 1990-10-08
HUT34446A (en) 1985-03-28
KR850001902A (en) 1985-04-10
PT79028A (en) 1984-09-01
IL72465A0 (en) 1984-11-30
FI843053A (en) 1985-02-06
ES8505980A1 (en) 1985-07-01
KR910009937B1 (en) 1991-12-06
ES534435A0 (en) 1985-06-16
GR80031B (en) 1984-12-11
ES8505979A1 (en) 1985-06-16

Similar Documents

Publication Publication Date Title
ES8505980A1 (en) Piperidine derivatives.
HUP0302337A2 (en) Pyrimidine-2,4,6-trione metalloproteinase inhibitors, pharmaceutical compositions containing them and their use
HUP0401575A2 (en) Novel vinyl carboxylic acid derivatives and their use as antidiabetics and pharmaceutical compositions containing them
HUP0001165A2 (en) Acylaminoalkenylene-amide derivatives as nk1 and nk2 antagonists, pharmaceutical compositions containing them and process for producing them
EP0204309A3 (en) Substituted n-benzyl-4(benzhydryl) piperidines
NO921159D0 (en) TIAZOLIDINON AND OXSAZOLIDINON DERIVATIVES, PROCEDURES FOR PREPARING THEREOF, AND USING THE DERIVATIVES AS VASODILATORS
KR927003589A (en) p-substituted phenyl 4-oxybutane amine derivatives, preparation method thereof and pharmaceutical composition containing the same
DE69029861D1 (en) N-ACYL-SUBSTITUTED AZACYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
SE7502243L (en)
AU2002244985A1 (en) Thiazolidinedione derivatives and pharmaceutical composition comprising the same
ES8601141A1 (en) Substituted isoquinoline derivatives, method for their preparation, and pharmaceutical compositions containing these compounds.
DE69126438D1 (en) 2-PHENYL AND 2-THIENYL (2) PIPERIDINE DERIVATIVES WITH NEUROPROTECTIVE PROPERTIES
AU4222397A (en) 2-carbonylthiazole derivative and use thereof

Legal Events

Date Code Title Description
PC1A Transfer granted
GC1A Exploitation certificate registered application without search report

Effective date: 19981013